

Laufende Klinische Versuche

Diagnosis	Study Title	Study Name / Product /Implimentation	Sponsor	Principal Investigator	Status / Start / End	Patient nr.
Metastatic Melanom	Columbus CMEK162B2301	A Phase III randomized, 3-arm, open label, multicenter study of LGX818 plus MEK162 and LGX818 monotherapy compared with Vemurafenib in patients with unresectable or metastatic BRAF V600 mutant melanoma	Novartis	Prof. Hunger	close to recrutment	4 of 7
Resected Stage II melanoma	MK-3475-716	Adjuvant Therapy with Pembrolizumab versus Placebo in Resected Stage II Melanoma : A Randomized, Double-Blind Study (Keynote716)	MSD	Prof. Hunger	recruiting	3 of 12
Basal cell carcinoma	NISSO	A non-interventional, multi-national, multi-center post-authorization safety study (PASS) to assess the long-term safety and tolerability of Odomzo® (sonidegib) administered in patients with locally advanced basal cell carcinoma (laBCC) - NISSO	Alcedis	Prof. Hunger	recruiting	5
Metastatic Melanom	CA045-001	A Phase 3, Randomized, Open-Label Study of NKTR-214 Combined with Nivolumab Versus Nivolumab in Participans with Previously Untreated Unresectable or Metastatic Melanoma	Bristol-Myers Squipp GesmbH	Prof. R. Hunger	recruiting	6

Laufende Forschungsprojekte (Pathologie und/oder nicht-invertentionell)

Diagnosis	Study Title	Study Name / Product /Implimentation	Sponsor	Principal Investigator	Status / Start / End	Patient nr.
melanozytäre Läsionen	LTML-Projekt	Histologische Charakteristiken von melanozytären Läsionen an den Beinen		Prof. Beltraminelli	2018	250
Subungual Melanoma		Weiterverwendung biologischer Materials und/oder gesundheitsbezogener Personendaten für die Forschung bei fehlender Einwilligung und Information nach Artikel 34HFG	Universitätsspital Basel	Prof. Beltraminelli	2019	
Tumor-Immunität	Th9 cells in human melanoma	Characterizing human T helper type 9 cells and their role in anti-melanoma immune response		Prof. Schlapbach	läuft	

Basal cell carcinoma		Basal cell carcinoma associated to dermatofibroma; induction phenomenon or true tumor?		PD Dr. med. L. Feldmeyer		
Basal cell carcinoma	PASS	A non-interventional, multi-national, multi-center post-authorization safety study (PASS) to assess the long-term safety and tolerability of Odomzo® (sonidegib) administered in patients with locally advanced basal cell carcinoma (laBCC)		Prof. Hunger	awaiting opening	

Klinische Forschungsprojekte der Universitätsklinik für Plastische Chirurgie

Malignes Melanom Merkelzellkarzinom	LIMIT	Lymph node Identification in skin Malignancy using indocyanine green Transcutaneously (LIMIT) Study. / A diagnostic sensitive study to analyse the ability of intradermally administered indocyanine green (ICG) and near infrared fluorescence imaging (NIRFI) to transcutaneously identify sentinel lymph nodes (SLNs) in malignant melanoma and Merkel cell carcinoma - after intradermally administered injection of technetium 99m and traditional lymphoscintigraphy (LS) - a clinical, prospective, single-arm, single-blind, single-Center Phase II Study	Universität Bern, Prof. Mihai Constantinescu	Dr. R. Olariu	recruitment completed	93
--	--------------	---	---	---------------	-----------------------	-----------

Klinische Versuche in Vorbereitung

Diagnosis	Study Title	Study Name / Product / Implementation	Sponsor	Principal Investigator	Status / Start / End	Patient nr.
Melanoma	2125-MEL-301	A randomized phase 3 comparison of IMO-2125 with Ipilimumab versus Ipilimumab alone in subjects with Anti-PD-1 refractory Melanoma	Idera	Prof. Hunger	awaiting opening	
Metastatic Melanoma	PSV Array 818-301	Encorafenib and Binimetinib	Array	Prof. Hunger		

Melanoma	5702000 Bering	Encorafenib + Binimetinib in patients with locally advanced, unresectable or metastatic BRAF _{V600} -mutated melanoma; a multi-centric, national, prospective, longitudinal, non-interventional study in Switzerland	Bering	Prof. Hunger		
-----------------	-----------------------	---	--------	--------------	--	--